Prognostic Significance of (18) F-Fluorodeoxyglucose - Positron Emission Tomography After Treatment in Patients With Limited Stage Small Cell Lung Cancer

Abstract

Objective: Small cell lung cancer (SCLC) represents 15% to 25% of lung cancers. Despite favorable initial treatment response rates, recurrence is likely and long-term prognosis dismal.Accurate measurement of therapy response is critical to determine which patients might be spared additional treatment, and potential side effects. Results: Twenty-two patients (~7%) had post-treatment PET: 11 positive, 11 negative. Median duration from last chemotherapy to PET was 36 days (range, 3 to 125 days). Median follow-up for all patients was 34.4 months (range, 6.8 to 65.9 months). Estimated median progression-free survival for all patients was 8.1 months (95% confidence intervals [CI], 4.3 to 11.9 months), 10.5 months for PET negative (95% CI, 8.1 to >57.8 months) and 4.3 months for PET positive patients (95% CI, 2.8 to >7.2 months) (P<0.007, log-rank test).

High Impact of 18F-FDG-PET on Management and Prognostic Stratification of Newly Diagnosed Small Cell Lung Cancer

“…Only two previous studies have evaluated the prognostic impact of PET in SCLC [22,23]. In a study of 38 patients by Pandit et al, patients with PET-positive disease on restaging had significantly worse 2-year survival than those with PETnegative disease (23% vs. 67%; p=0.0108).…”

Prognostic significance of standardised uptake value (SUVmax ) measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer

“…The percentile (%) change in SUV max during and after treatment might be a better surrogate marker of clinical efficacy of chemotherapy compared to a single pre-treatment SUV value (Onitilo et al 2008). Data about the utility of PET to evaluate response to therapy in patients with SCLC are rare.…”

Therapy Response Evaluation With Fdg-Pet/Ct In Thoracic Malignancies

“…KHAK hastalarında KRT'ye olan yanıt KHDAK hastalarına göre çok daha çabuk geliştiğinden bu hasta grubunda morfolojik değerlendirme daha erken dönemde yapılabilmektedir. PET/BT ile yapılan metabolik değerlendirmenin sağkalım ile ilgisinin araştırıldığı sınırlı sayıdaki çalışmada metabolik yanıtlı grupta daha uzun sağkalım olduğu saptanmıştır (22,23). PERCIST ve EORTC kriterlerine göre FDG-PET/BT ile yapılan metabolik değerlendirmenin sonuçları arasında anlamlı fark saptanmadığı da bildirilmektedir (24).…”